OCDX earnings

RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022. Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Thos

Highlights  • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales  • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2 assay sales  • Fourth quarter Operating income was $31.1 million, while Adjusted EBITDA was $127.9 million  • Fiscal year Operating income was $173.9 million, while Adjusted EBITDA was $548.1 million, up 20.2% year-over-year RARITAN, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial

Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) (the "Company"), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022. Selected Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results (Unaudit

Strategic, transformational acquisition advances Quidel's global leadership in diagnostics Transaction Highlights Brings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Provides Quidel's expansive point-of-care diagnostics portfolio with access to Ortho's broad global reach across 130-plus countries, accelerating growth for Quidel's existing product portfolio and providing exposure to new, emerging markets. Deepens innovation pipeline, diversifies product portfolio, and accelerates product growth, driving sustainable revenue in a combined total addressable market of $

Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics Highlights  Third quarter revenue increased 15.8% to $522.5 million, or 14.3% in constant currency   Core revenue grew 14.8% to $508.9 million for the quarter, or 13.2% in constant currency   Strength across all major geographic regions, including double-digit growth in both developed and emerging markets   Operating income increased 161.0% to $54.0 million from $20.7 million last year   GAAP Net Income was $14.7 million, or $0.06 per diluted share, while Adjusted Net Income was $50.9 million, or $0.21 per diluted share in the third quarter of 2021   Third quarter Adjuste

RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its third quarter 2021 ended October 3, 2021, after the market close on Wednesday, November 3, 2021. Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the

Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics RARITAN, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today announced financial results for the second quarter ended July 4, 2021. Highlights Second quarter revenue increased 26.1% to $492.5 million, or 22.4% in constant currencyCore revenue grew 26.2% to $487.5 million for the quarter, or 22.5% in constant currency Operating Income increased 104.7% to $31.3 million from $15.3 million last yearGAAP Net Loss was ($20.0) million, or ($0.09) per diluted share,

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (NASDAQ:OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021. Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results. Interested parties can access the call and accompanying presentation on the "Investors" portion of the Company's website at https://ir.orthoclinicaldiagnostics.com/. Presentation materials will also be posted to the "Investors" portion of the website at the time of the call. Those unable to